168 related articles for article (PubMed ID: 25336699)
1. New, tolerable γ-secretase inhibitor takes desmoid down a notch.
Hughes DP; Kummar S; Lazar AJ
Clin Cancer Res; 2015 Jan; 21(1):7-9. PubMed ID: 25336699
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Messersmith WA; Shapiro GI; Cleary JM; Jimeno A; Dasari A; Huang B; Shaik MN; Cesari R; Zheng X; Reynolds JM; English PA; McLachlan KR; Kern KA; LoRusso PM
Clin Cancer Res; 2015 Jan; 21(1):60-7. PubMed ID: 25231399
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
[TBL] [Abstract][Full Text] [Related]
4. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
[TBL] [Abstract][Full Text] [Related]
7. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
[TBL] [Abstract][Full Text] [Related]
8. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.
Lanz TA; Wood KM; Richter KE; Nolan CE; Becker SL; Pozdnyakov N; Martin BA; Du P; Oborski CE; Wood DE; Brown TM; Finley JE; Sokolowski SA; Hicks CD; Coffman KJ; Geoghegan KF; Brodney MA; Liston D; Tate B
J Pharmacol Exp Ther; 2010 Jul; 334(1):269-77. PubMed ID: 20363853
[TBL] [Abstract][Full Text] [Related]
10. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
[TBL] [Abstract][Full Text] [Related]
11. [Alzheimer's disease treatment by inhibition/modulation of the gamma-secretase activity].
Tomita T
Rinsho Shinkeigaku; 2009 Nov; 49(11):845-7. PubMed ID: 20030227
[TBL] [Abstract][Full Text] [Related]
12. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
López-Guerra M; Xargay-Torrent S; Rosich L; Montraveta A; Roldán J; Matas-Céspedes A; Villamor N; Aymerich M; López-Otín C; Pérez-Galán P; Roué G; Campo E; Colomer D
Leukemia; 2015 Jan; 29(1):96-106. PubMed ID: 24781018
[TBL] [Abstract][Full Text] [Related]
13. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
Du Z; Li L; Sun W; Wang X; Zhang Y; Chen Z; Yuan M; Quan Z; Liu N; Hao Y; Li T; Wang J; Luo C; Wu X
Int J Oncol; 2018 Jul; 53(1):99-112. PubMed ID: 29658567
[TBL] [Abstract][Full Text] [Related]
14. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
Chan D; Kaplan J; Gordon G; Desai J
Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
[TBL] [Abstract][Full Text] [Related]
16. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M; Ratan R; Alcindor T; Schöffski P; van der Graaf WT; Wilky BA; Riedel RF; Lim A; Smith LM; Moody S; Attia S; Chawla S; D'Amato G; Federman N; Merriam P; Van Tine BA; Vincenzi B; Benson C; Bui NQ; Chugh R; Tinoco G; Charlson J; Dileo P; Hartner L; Lapeire L; Mazzeo F; Palmerini E; Reichardt P; Stacchiotti S; Bailey HH; Burgess MA; Cote GM; Davis LE; Deshpande H; Gelderblom H; Grignani G; Loggers E; Philip T; Pressey JG; Kummar S; Kasper B
N Engl J Med; 2023 Mar; 388(10):898-912. PubMed ID: 36884323
[TBL] [Abstract][Full Text] [Related]
17. γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment.
Jia H; Wang Z; Zhang J; Feng F
Life Sci; 2021 Mar; 268():119007. PubMed ID: 33428878
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014.
Brodney MA; Auperin DD; Becker SL; Bronk BS; Brown TM; Coffman KJ; Finley JE; Hicks CD; Karmilowicz MJ; Lanz TA; Liston D; Liu X; Martin BA; Nelson RB; Nolan CE; Oborski CE; Parker CP; Richter KE; Pozdnyakov N; Sahagan BG; Schachter JB; Sokolowski SA; Tate B; Wood DE; Wood KM; Van Deusen JW; Zhang L
Bioorg Med Chem Lett; 2011 May; 21(9):2637-40. PubMed ID: 21269827
[TBL] [Abstract][Full Text] [Related]
19. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
Zhang CC; Yan Z; Giddabasappa A; Lappin PB; Painter CL; Zhang Q; Li G; Goodman J; Simmons B; Pascual B; Lee J; Levkoff T; Nichols T; Xie Z
Cancer Med; 2014 Jun; 3(3):462-71. PubMed ID: 24573979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
